Market Newsdesk

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

• Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90% in the pediatric population
• An oral presentation at ISPPD highlighted an approximately 9 to 15-fold higher serotype 3 immunogenicity response after Dose 3 and 4 in infants receiving Pfizer’s 25-valent vaccine candidate (25vPnC) compared to PREVNAR 20®
• The investigational vaccine candidate was well-tolerated with no safety concerns identified in a Phase 2 study
• Based on these encouraging results from the Phase 2 program across serotypes and discussions with regulatory authorities, Pfizer initiated its Phase 3 25vPnC pediatric program
• Company advances adult program to fifth generation 35-valent vaccine candidate

NEW YORK–(BUSINESS WIRE)–
Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of PREVNAR 20 at months 2, 4, 6 and 12-15. Based on the strong immune responses observed for all 25vPnC serotypes from Phase 2, compared to PREVNAR 20, Pfizer is confident that the required non-inferiority thresholds may be achieved for the 25vPnG pediatric Phase 3 program.

Key preliminary data from the broader Phase 2 study were presented today in an oral presentation at the 14th meeting of the International Society of Pneumonia & Pneumococcal Diseases in Copenhagen, Denmark (ISPPD). Results found:

• One month after Dose 3, geometric mean titers for serotype 3 were 8.8-fold higher with 25vPnC than with PREVNAR 20 (4.22 vs. 0.48).
• One month after Dose 4, geometric mean titers for serotype 3 were approximately 15-fold higher with 25vPnC than with Prevnar 20 (13.85 vs. 0.92).
• This vaccine candidate is expected to cover up to 90% of disease-causing serotypes in children under 5 years of age, which includes approximately 15% from serotype 3.

“For more than 25 years, our vaccines have helped protect children from pneumococcal disease, yet significant disease burden remains,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. “These Phase 2 results reinforce our confidence in a next-generation vaccine designed to expand protection across serotypes while improving responses to key residual disease drivers such as serotype 3. We are advancing our Phase 3 program with the goal of delivering broader and more durable protection for children.”

The Phase 2 study is a randomized trial in healthy infants, with initial enrolment beginning in July 2024, evaluating 25vPnC compared with PREVNAR 20. Participants were randomized to receive 25vPnC or PREVNAR 20 at months 2, 4, 6 and 12–15 assessing the safety and tolerability, including local and systemic reactogenicity within seven days after each vaccination, as well as adverse events and serious adverse events in participants who receive at least one dose. The trial also assessed immunogenicity one month after Dose 3 and one month after Dose 4, compared to one month after Dose 3 and Dose 4 with PREVNAR 20.

The safety and tolerability profile of 25vPnC was consistent with the currently approved and available pneumococcal vaccine. The most common local reactions were redness, swelling or pain at injection site similar to existing vaccines.

Advancing Pediatric and Adult into Pivotal Phase 3 Studies

Despite significant reduction in pneumococcal disease burden by the currently available 20-valent standard-of-care-vaccine, serotype 3 remains a notable cause of invasive pneumococcal disease and complicated pneumonia in children. Therefore, based on this Phase 2 data and discussions with regulatory authorities, Pfizer began a pivotal pediatric Phase 3 program in May 2026. The studies evaluate safety, tolerability and immunogenicity of 25vPnC in healthy children where participants receive either 25vPnC or PCV20 at 2, 4, 6 and 12 to 15 months of age. Participants will receive the same vaccine for all four vaccinations for up to 2,400 individuals comparing 25vPnC to the currently licensed 20-valent standard-of-care vaccine.

The vaccine candidate covers 25 serotypes including serotype 3, adding five new serotypes to the established vaccine coverage for infants. If successful, this has the potential to broaden protection to about 90% of disease-causing serotypes in US children.

Meanwhile, as the strongest opportunity to maintain the company’s current leadership in the adult market over the long term, Pfizer has decided to move directly to a fifth-generation vaccine candidate covering 35 serotypes. This fifth-generation adult candidate has the potential to increase serotype coverage while also improving immunogenicity for critical serotypes including serotype 3 with Pfizer’s proprietary next generation technology. The adult vaccine candidate is expected to enter clinical development by the end of 2026, pending alignment with regulatory authorities.

About 25vPnC (25-valent pneumococcal conjugate vaccine candidate)

Pfizer’s 4th-generation pneumococcal conjugate vaccine candidate builds on the 20 serotypes already covered by PCV20 (PREVNAR 20). It adds five additional serotypes — 15A, 23A, 23B, 24F, and 35B that represents additional 25% coverage of IPD cases compared with PCV20 to broaden coverage to 25 serotypes total, including cross-reactivity. Beyond expanding serotype coverage, 25vPnC also aims to enhance protection against serotype 3, which remains a key driver of residual pneumococcal disease. To achieve this, 25vPnC utilizes next-generation technology specifically designed to elicit a more robust immune response against serotype 3.

U.S. INDICATION AND IMPORTANT SAFETY INFORMATION FOR PREVNAR 20

INDICATION

PREVNAR 20 is a vaccine approved for:

• the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in individuals 6 weeks of age and older.

• the prevention of otitis media (middle ear infection) caused by 7 of the 20 strains in individuals 6 weeks through 5 years.

• active immunization for the prevention of pneumonia caused by Streptococcus pneumoniae strains 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older.

The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved based on immune responses. Continued approval may depend on a supportive study.

IMPORTANT SAFETY INFORMATION

• PREVNAR 20 should not be given to anyone who has had a severe allergic reaction to any component of Prevnar 20 or to diphtheria toxoid.

• Individuals with weakened immune systems may have a lower immune response. Safety data are not available for these groups.

• A temporary pause in breathing after getting a vaccine has been observed in some infants who were born prematurely. For premature infants, talk to your healthcare provider about the infant’s medical status when deciding to get vaccinated with Prevnar 20.

• In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most common side effects reported at a rate of >10% were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever.

• In individuals 15 months through 17 years of age vaccinated with a single dose, the most common side effects reported at a rate of >10% were irritability, pain at the injection site, drowsiness, fatigue, muscle pain, decreased appetite, injection site swelling, injection site redness, headache, and fever.

• In individuals 18 years and older, the most common side effects reported at a rate of >10% were pain at the injection site, muscle pain, fatigue, headache, and joint pain. Also, injection site swelling was common in individuals 18 years through 59 years of age.

• Ask your healthcare provider about the risks and benefits of Prevnar 20. Only a healthcare provider can decide if PREVNAR 20 is right for you or your child.

Please click for PREVNAR 20 Full Prescribing Information.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice

The information contained in this release is as of May 20, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an investigational pediatric 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) and an investigational adult fifth-generation vaccine candidate covering 35 serotypes (35vPnC), including their potential benefits, results from a Phase 2 study of 25vPvC in infants and clinical development plans and timing for 25vPnC and 35vPnC, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications may be filed in any jurisdictions for 25vPnC or 35vPnC; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether 25vPnC and 35vPnC will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of 25vPnC and 35vPnC; uncertainties regarding the ability to obtain or maintain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S.; challenges related to public vaccine confidence or awareness; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Category: Research and Pipeline

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520512448/en/

Pfizer Media Contact:

[email protected]

Pfizer Investor Relations:

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo

CoStar Data Shows Glasgow City Centre Office Leasing Hits 230,000 Sq. Ft. in Q1 2026

LONDON–(BUSINESS WIRE)–
Glasgow’s city centre recorded its highest quarterly office take-up since 2021, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520059572/en/

Take-up in the first three months of the year rose 85% quarter-on-quarter and 34% year-on-year. On a rolling four-quarter basis, occupier demand remained stable at around 600,000 sq. ft., up more than a third on the average between H2 2022 and H1 2024.

“Activity was driven by a return of larger deals, with three lettings above 20,000 sq. ft. signed in the city centre in Q1, more than in the whole of 2025,” said Grant Lonsdale, senior director of market analytics at CoStar Europe. “This pushed the average city centre deal size to around 6,000 sq. ft. in Q1 and 4,600 sq. ft. on a rolling annual basis, roughly 50% higher than two years earlier and the highest since Q3 2021.”

A total of 28 lettings below 5,000 sq. ft. were recorded in the City Core in Q1, taking the rolling four-quarter total to 133, nearing a record high.

Vacancy remains elevated at 12.4% across Glasgow and 15.8% in the city centre.

The full analysis can be found here.

For more information about the company and its products and services, please visit www.costargroup.com.

About CoStar Group

CoStar Group (NASDAQ: CSGP) is a global leader in commercial real estate information, analytics, online marketplaces, and 3D digital twin technology. Founded in 1986, CoStar Group is dedicated to digitizing the world’s real estate, empowering all people to discover properties, insights, and connections that improve their businesses and lives.

CoStar Group’s major brands include CoStar, a leading global provider of commercial real estate data, analytics, and news; LoopNet, the most trafficked commercial real estate marketplace; Apartments.com, the leading platform for apartment rentals; Homes.com, the fastest-growing residential real estate marketplace; and Domain, one of Australia’s leading property marketplaces. CoStar Group’s industry-leading brands also include Matterport, a leading spatial data company whose platform turns buildings into data to make every space more valuable and accessible; STR, a global leader in hospitality data and benchmarking; Ten-X, an online platform for commercial real estate auctions and negotiated bids; and OnTheMarket, a leading residential property portal in the United Kingdom.

CoStar Group’s websites attracted over 131 million average monthly unique visitors in the first quarter of 2026, serving clients around the world. Headquartered in Arlington, Virginia, CoStar Group is committed to transforming the real estate industry through innovative technology and comprehensive market intelligence. From time to time, we plan to utilize our corporate website as a channel of distribution for material company information. For more information, visit CoStarGroup.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520059572/en/

Karolina Capova

Senior Media Relations Specialist

[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Data Analytics Professional Services Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Photo

Glasgow City Centre Office Leasing Hits 230,000 Sq. Ft. in Q1 2026

Logo

CrowdStrike Named the Overall Champion in the Omdia 2026 Cybersecurity Platform Ecosystems Leadership Matrix

Positioned highest and furthest to the right among 24 vendors; recognized for best-in-class partner ecosystem growth and continued platform leadership powering cybersecurity

AUSTIN, Texas–(BUSINESS WIRE)–CrowdStrike (NASDAQ: CRWD) today announced it has been named the Overall Champion in the Omdia 2026 Cybersecurity Platform Ecosystems Leadership Matrix, positioned highest and furthest to the right among 24 vendors. Reflecting analyst assessment, partner feedback, and performance metrics, the recognition underscores CrowdStrike’s leadership in building and scaling a global partner ecosystem on the CrowdStrike Falcon® platform.

“Cybersecurity is an ecosystem game, and the platform decides who wins,” said Daniel Bernard, chief business officer at CrowdStrike. “Omdia’s recognition reinforces what our partners and customers tell us every day – they’re standardizing on the Falcon platform and building on it. This is what it looks like when the ecosystem is built on the platform, not bolted on. That’s what scales, and that’s what stops breaches.”

The Omdia report cites “a diverse, scaled partner ecosystem driving sustained best-in-class growth across co-sell motions, services, and marketplaces.” Omdia also recognized CrowdStrike for:

• Expanding Next-Gen SIEM and MSSP momentum: GSIs expanded CrowdStrike Falcon® Next-Gen SIEM practices while MSSP activity increased, with MSSP business scaling to more than $1.3 billion in total contract value over the past three years, as of 4Q26.
• Scaling hyperscaler marketplaces: AWS Marketplace contract value nearing $1.5 billion in FY26, alongside hundreds of millions through Google Cloud Marketplace, and expansion to Microsoft Marketplace.
• Enabling partner-led delivery: Expanding service delivery with partners including Accenture, Deloitte, EY, Kroll, and Wipro.
• Expanding the AI and hyperscaler ecosystem: Deepening alliances with AWS, Google, Microsoft, and NVIDIA; partnerships with Anthropic, OpenAI, and Perplexity; AI infrastructure collaborations with CoreWeave and Nebius; and EU sovereign cloud alignment with Schwarz Digits.
• Driving flexible consumption: Strengthening the Accelerate Partner Program with expanded incentives, predictable pricing, and greater licensing flexibility through Falcon Flex, including consumption-based services.
• Building the AI partner ecosystem: Launching the Charlotte AI AgentWorks ecosystem to enable partners to build and commercialize custom AI security agents.

“CrowdStrike’s ecosystem strategy reflects a clear shift from traditional partnerships to a platform model where partners can build, monetize, and deliver differentiated services at scale,” said Matthew Ball, Chief Analyst, Enterprise & Channel at Omdia. “Its expansion across hyperscalers, AI partners, and marketplaces – combined with new opportunities to develop and commercialize AI-driven services – positions CrowdStrike to drive the next phase of ecosystem growth.”

“CrowdStrike continues to raise the bar for what a modern cybersecurity platform ecosystem should look like,” said Mark Thornberry, SVP, Partnerships at GuidePoint Security. “We’ve built an incredible business together, and it remains one of the strongest partnerships we have today. The Falcon platform continually creates new opportunities for us to grow and deliver meaningful security outcomes for customers.”

To learn more about CrowdStrike’s recognition in the Omdia 2026 Cybersecurity Platform Ecosystems Leadership Matrix, visit our website.

Forward-Looking Statements

This press release may include discussion of unreleased services or features. Any unreleased services or features referenced here are still in development and subject to change. Customers should make their purchase decisions based upon features that are currently available.

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | X | LinkedIn | Instagram

Start a free trial today: https://www.crowdstrike.com/trial

© 2026 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514823546/en/

Media Contact

Jake Schuster

CrowdStrike Corporate Communications

[email protected]

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Security Data Management Technology Artificial Intelligence Software

MEDIA:

Logo

Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry

IIOR Shows Record Outsourced Insurance AUM, Private Assets Near $1 Trillion, and Europe Emerging as a Global Growth Engine

BOISE, Idaho & NEW YORK & CHICAGO & LONDON & HONG KONG–(BUSINESS WIRE)–Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/

The 2026 IIOR reveals defining trends reshaping insurance investment management:

Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and approaching one-third of outsourced insurance allocations alongside public assets. Insurers have moved steadily beyond traditional private placements into middle-market lending, infrastructure debt, and structured credit, and 67% of participating managers now offer private fixed income capabilities alongside their public strategies.

Europe Rewrites the Map. Europe and the UK represent a major and expanding force in insurance outsourcing, with reported AUM growing 32% year-over-year and more than doubling since 2021, from $1.0 trillion to $2.1 trillion, reflecting both organic growth and broader manager participation in the IIOR. Europe and the UK now account for 38% of total outsourced insurance AUM. On a percentage basis, APAC and offshore markets grew even faster year-over-year, each significantly outpacing North America’s still-solid 12% gain. The findings reflect an outsourcing market that is no longer centered primarily in North America. Managers are increasingly winning mandates through global scale, regional specialization, or both.

“The 2026 IIOR captures a transformation that no single number can fully convey. Private markets have crossed a threshold, Europe has reshaped the map, and the sophistication this industry now demands across asset classes, geographies, and regulatory environments is compounding,” said Sandeep Sahai, Chief Executive Officer of Clearwater Analytics. “We believe the power of partnership is what allows insurers and their managers to move with the confidence this moment requires. We invite you to read the full report and see what this transformation means for your business.”

“What the 2026 IIOR makes clear is that insurance outsourcing is the prevailing model for how insurers deploy capital globally,” said Steve Doire, owner of DCS Financial Consulting and Strategic Advisor to Clearwater Analytics. “The near doubling of consultant AUA in two years tells you that insurers are engaging experts to build and manage increasingly diverse and complex strategic investment programs. The European surge is equally significant. This market has moved well beyond North American dominance, and the managers best positioned for what comes next are those who recognized this global shift and invested in the capability and presence to win across regions.”

A More Competitive Market Takes Shape

The growth of the IIOR reflects the growth of the market itself. What began as a report covering 40 participants now includes 108 managers and consultants and $5.5 trillion in assets under management. Over the past decade, the top 10 managers’ share of total AUM has declined from 70% to 59%, showing that more firms are competing for insurance mandates. Specialized and mid-sized managers are gaining ground through insurance expertise, private markets capabilities, and regional strength. Consultant AUA has also nearly doubled in two years, as insurers turn to outside expertise to help manage more complex investment programs.

What the Report Covers

The 2026 IIOR includes 96 asset manager profiles, 12 investment consultant profiles, global and regional rankings, and data on asset allocations, client types, and regional growth across major insurance investment markets. Together, these findings provide a clear view of where insurance assets are being managed, which firms are gaining share, and how the market is changing. The report is produced with DCS Financial Consulting, with Institutional Investor serving as industry engagement partner.

Download the 2026 IIOR today.

About DCS Financial Consulting

DCS Financial Consulting is a leading advisory firm specializing in insurance investment strategy for both asset managers and insurers. Steve Doire, owner and founder, fundamentally transformed the IIOR nearly a decade ago and has led it ever since.

About CWAN

Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, CWAN’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, CWAN supports over $10 trillion in assets globally.Learn more at www.cwan.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520780028/en/

Media:

Claudia Cahill, Head of Communications and PR | +1 208-433-1200 | [email protected]

KEYWORDS: Illinois Idaho New York United States United Kingdom Hong Kong North America Asia Pacific Europe

INDUSTRY KEYWORDS: Professional Services Data Management Technology Insurance Finance Asset Management Consulting

MEDIA:

Photo

Logo